SYRE250117C15000
- 11.10
- 0.000.00%
Spyre Therapeutics Newsroom
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $70
Promising Potential of Spyre Therapeutics' SPY002 Drives Buy Rating Amid Robust Anti-TL1A Market
Spyre Therapeutics Analyst Ratings
JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Spyre Therapeutics Is Maintained at Outperform by Baird
Spyre Therapeutics Analyst Ratings
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $70
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Spyre Therapeutics Analyst Ratings
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Promising Advancements in Spyre Therapeutics' Programs Drive Buy Rating
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40